Clinical Trial Update: A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SAGE-718 in Parkinson's disease with cognitive impairment has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Parkinson Disease, Cognitive Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2025-02-06